Patent application number | Description | Published |
20090104224 | MODIFIED VACCINIA VIRUS ANKARA FOR THE VACCINATION OF NEONATES - The invention concern the use of a virus for the preparation of a medicament for the vaccination or treatment of a neonatal or prenatal animal, including a human, wherein the virus is capable of infecting the cells of the neonatal or prenatal animal, including a human, but not capable of being replicated to infectious progeny virus in the neonatal or prenatal animal, including a human. The virus is preferably a Modified Vaccinia Virus Ankara. | 04-23-2009 |
20090169579 | Modified vaccinia Ankara virus avriant - The present invention provides an attenuated virus, which is derived from Modified Vaccinia Ankara virus, wherein the MVA-BN virus, or a derivative thereof, induces at least substantially the same level of immunity in vaccinia virus prime/vaccina virus boost regimes when compared to DNA prime/vaccinia virus boost regimes. It further describes recombinant viruses derived from this virus and the use of the virus, or its recombinants, as a medicament or vaccine. A method is provided for inducing an immune response in individuals who may be immune-compromised, receiving antiviral therapy, or have a pre-existing immunity to the vaccine virus. | 07-02-2009 |
20100119545 | MODIFIED VACCINIA ANKARA VIRUS VARIANT - The present invention provides an attenuated virus, which is derived from Modified Vaccinia Ankara virus, wherein the MVA-BN virus, or a derivative thereof, induces at least substantially the same level of immunity in vaccinia virus prime/vaccina virus boost regimes when compared to DNA prime/vaccinia virus boost regimes. It further describes recombinant viruses derived from this virus and the use of the virus, or its recombinants, as a medicament or vaccine. A method is provided for inducing an immune response in individuals who may be immune-compromised, receiving antiviral therapy, or have a pre-existing immunity to the vaccine virus. | 05-13-2010 |
20100183663 | INTERGENIC REGIONS AS NOVEL SITES FOR INSERTION OF HIV DNA SEQUENCES IN THE GENOME OF MODIFIED VACCINIA VIRUS ANKARA - The invention relates to novel insertion sites useful for the integration of HIV DNA sequences into the MVA genome, and to the resulting recombinant MVA derivatives. | 07-22-2010 |
20100196992 | INTERGENIC REGIONS AS NOVEL SITES FOR INSERTION OF HIV DNA SEQUENCES IN THE GENOME OF MODIFIED VACCINIA VIRUS ANKARA - The invention relates to novel insertion sites useful for the integration of HIV DNA sequences into the MVA genome, and to the resulting recombinant MVA derivatives. | 08-05-2010 |
20100279386 | MODIFIED VACCINIA ANKARA VIRUS VARIANT AND CULTIVATION METHOD - The present invention provides an attenuated virus, which is derived from Modified Vaccinia Ankara virus and characterized by the loss of its capability to reproductively replicate in human cell lines. It further describes recombinant viruses derived from this virus and the use of the virus, or its recombinants, as a medicament or vaccine. A method is provided for inducing an immune response in individuals who may be immune-compromised, receiving antiviral therapy, or have a pre-existing immunity to the vaccine virus. In addition, a method is provided for the administration of a therapeutically effective amount of the virus, or its recombinants, in a vaccinia virus prime/vaccinia virus boost innoculation regimen. The present invention relates to a method of virus amplification in primary cells which are cultivated in a serum free medium. Viruses produced by this method are advantageously free of any infectious agents comprised in animal sera. | 11-04-2010 |
20110142877 | Use of a modified poxvirus for the rapid induction of immunity against a poxvirus or other infectious agents - The present invention relates to the rapid induction of a protective immune response against infectious agents using a poxvirus. An immune response can be induced by administering the poxvirus 7 to 2 days prior to infection with the infections agents. | 06-16-2011 |
20110182932 | MODIFIED VACCINIA ANKARA VIRUS VARIANT - The present invention provides an attenuated virus, which is derived from Modified Vaccinia Ankara virus, wherein the MVA-BN virus, or a derivative thereof, induces at least substantially the same level of immunity in vaccinia virus prime/vaccina virus boost regimes when compared to DNA prime/vaccinia virus boost regimes. It further describes recombinant viruses derived from this virus and the use of the virus, or its recombinants, as a medicament or vaccine. A method is provided for inducing an immune response in individuals who may be immune-compromised, receiving antiviral therapy, or have a pre-existing immunity to the vaccine virus. | 07-28-2011 |
20110182933 | MODIFIED VACCINIA ANKARA VIRUS VARIANT - The present invention provides an attenuated virus, which is derived from Modified Vaccinia Ankara virus, wherein the MVA-BN virus, or a derivative thereof, induces at least substantially the same level of immunity in vaccinia virus prime/vaccina virus boost regimes when compared to DNA prime/vaccinia virus boost regimes. It further describes recombinant viruses derived from this virus and the use of the virus, or its recombinants, as a medicament or vaccine. A method is provided for inducing an immune response in individuals who may be immune-compromised, receiving antiviral therapy, or have a pre-existing immunity to the vaccine virus. | 07-28-2011 |
20110306093 | INTERGENIC REGIONS AS NOVEL SITES FOR INSERTION OF HIV DNA SEQUENCES IN THE GENOME OF MODIFIED VACCINIA VIRUS ANKARA - The invention relates to novel insertion sites useful for the integration of HIV DNA sequences into the MVA genome, and to the resulting recombinant MVA derivatives. | 12-15-2011 |
20120009214 | INTERGENIC REGIONS AS NOVEL SITES FOR INSERTION OF HIV DNA SEQUENCES IN THE GENOME OF MODIFIED VACCINIA VIRUS ANKARA - The invention relates to novel insertion sites useful for the integration of HIV DNA sequences into the MVA genome, and to the resulting recombinant MVA derivatives. | 01-12-2012 |
20120014922 | INTERGENIC REGIONS AS NOVEL SITES FOR INSERTION OF HIV DNA SEQUENCES IN THE GENOME OF MODIFIED VACCINIA VIRUS ANKARA - The invention relates to novel insertion sites useful for the integration of HIV DNA sequences into the MVA genome, and to the resulting recombinant MVA derivatives. | 01-19-2012 |
20120015423 | INTERGENIC REGIONS AS NOVEL SITES FOR INSERTION OF HIV DNA SEQUENCES IN THE GENOME OF MODIFIED VACCINIA VIRUS ANKARA - The invention relates to novel insertion sites useful for the integration of HIV DNA sequences into the MVA genome, and to the resulting recombinant MVA derivatives. | 01-19-2012 |
20120107359 | USE OF A MODIFIED POXVIRUS FOR THE RAPID INDUCTION OF IMMUNITY AGAINST A POXVIRUS OR OTHER INFECTIOUS AGENTS - The present invention relates to the rapid induction of a protective immune response against infectious agents using a poxvirus. An immune response can be induced by administering the poxvirus 7 to 2 days prior to infection with the infections agents. | 05-03-2012 |